A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

NCT04449276 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

280

Enrollment

INDUSTRY

Sponsor class

Conditions

Severe Acute Respiratory Syndrome
Coronavirus
SARS-CoV-2
COVID-19

Interventions

BIOLOGICAL: CVnCoV Vaccine
DRUG: Placebo

Sponsor

CureVac

Collaborators

[object Object]